Clinical trial NCT04260932: CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients
Official title: CD19/CD20 Dual-CAR-T for Patients With B-cell Lymphoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: B-cell Lymphoma
Lead sponsor: Hebei Yanda Ludaopei Hospital
Sponsor class: OTHER
Collaborators: name: China Immunotech (Beijing) Biotechnology Co., Ltd.
First posted: 2020-02-07
Enrollment: 12
Sex: ALL
Minimum age (years): 1
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of CD19/CD20 Dual-CAR-T cells in patients with refractory and relapsed B-cell lymphoma.

Detailed description: This Phase I study is designed as a pilot trial evaluating the safety and efficacy of CD19/CD20 Dual-CAR-T cell therapy in subjects with refractory and relapsed B cell lymphoma. Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of CD19/CD20 Dual-CAR-T cells. Safety and efficacy of CD19/CD20 Dual-CAR-T cells therapy will be monitored. The purpose of current study is to determine the clinical efficacy and safety of CD19/CD20 Dual-CAR-T cells therapy in patients with refractory and relapsed B-cell lymphoma.

Eligibility criteria: Inclusion Criteria:

1. Relapsed and refractory B-cell lymphoma with:

   Relapsed or refractory disease after ≥2 lines of chemotherapy including rituximab and anthracycline and either having failed after autologous or allogeneic hematopoietic stem cell transplantation (ASCT);
2. Patients must have evaluable evidence of disease, including minimal residual disease (MRD);
3. Double positive expression of CD19 / CD20 in B cells;
4. Ages 1 to 80 years, including boundary values;
5. ECOG score 0-3 points;
6. Women of childbearing age (15-49 years old) must receive a pregnancy test within 7 days prior to initiation of treatment and the results are negative; male and female patients with fertility must use an effective contraceptive to ensure 3 months after discontinuation of treatment during the study period not pregnant inside;
7. Patients who voluntarily sign informed consent and are willing to comply with treatment plans.

Exclusion Criteria:

1. patients with organ failure:

   * Heart: NYHA heart function grade IV;
   * Liver: Grade C that achieves Child-Turcotte liver function grading;
   * Kidney: kidney failure and uremia;
   * Lung: symptoms of respiratory failure;
   * Brain: a person with a disability;
2. Active infections that are difficult to control;
3. Human immunodeficiency virus (HIV) positive;
4. Liver and kidney function: total bilirubin \> 5 × ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \> 5 × ULN, serum creatinine clearance rate 60mL / min;
5. GVHD ≥ 2 or anti-GVHD treatment;
6. intracranial hypertension or unconsciousness; respiratory failure; diffuse vascular internal coagulation;
7. pregnant or lactating women;
8. The patient does not agree to use effective contraception during the treatment period and for the next 3 months;
9. Patients who participate in other clinical studies at the same time;
10. The investigator believes that there are other factors that are not suitable for inclusion or influence the subject's participation or completion of the study.

Primary outcomes:
measure: Percentage of participants with adverse events.
timeFrame: 6 months
measure: Objective remission rate(ORR)
timeFrame: 6 months
Secondary outcomes:
measure: Relapse-Free Survival(RFS )
timeFrame: 6 months
measure: Overall-Survival(OS)
timeFrame: 6 months
measure: Persistence of CAR-T cells in vivo
timeFrame: 6 months
Other outcomes:
Locations:
city: Sanhe
country: China
facility: Hebei Yanda Ludaopei Hospital
state: Hebei
Study officials:
References: